t: 646-358-1907, e:
Joseph Pantginis, Ph.D. is a Senior Research Analyst
and Head of Biotechnology Research. Dr. Pantginis joined ROTH Capital Partners in 2009. Prior to joining ROTH, Dr. Pantginis was a senior biotech analyst at Merriman Curhan Ford. Dr. Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JBHanauer & Co., First Albany Corporation, Commerce Capital Markets and Ladenburg Thalmann & Co., Inc. Prior to his tenure on Wall Street, Dr. Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Dr. Pantginis received an M.B.A. in Finance from Pace University; a Ph.D. in Molecular Genetics and an M.S. from Albert Einstein College of Medicine; and a B.S. from Fordham University.